Liantuo Biopharmaceutical Technology Co., Ltd. with investment from SDIC Investment Management Co., Ltd. got listed on Nasdaq on November 1, 2021, code named LIAN.

Liantuo Biopharmaceutical Technology Co., Ltd. (Lianbio) is specialized in providing innovative medicines for clients in China, Asia and other major markets. Soon after its establishment, Lianbio started cooperation with top-notch biotech companies in the world through its rich resources and with such collaboration, Lianbio completed the launch of diversified clinical drug product candidates pipeline. At present, the company has nine candidate drug products targeting at 15 adaptive diseases, covering the five major disease fields of cardiovascular, tumor, ophthalmology, inflammatory disease and respiratory system, of which quite a few are at the stage of clinical development.

Lianbio cooperates with BMS in the field of cardiovascular disease for the treatment of hypertrophic cardiomyopathy (HCM); in the field of ophthalmic disease, it cooperates with Tarsus to develop and commercialize TP-03 (eye drops) for the treatment of DB, which also has the potential for the treatment of meibomian gland dysfunction (MGD); in the field of tumor, it cooperates with Nanobiotix to develop radiosensitizer and immunologic therapy; in the field of inflammatory disease, it cooperates Landos to develop and commercialize omilancor project used for the treatment of inflammatory bowel disease (IBD); in the field of respiratory system, it cooperates with ReViral to jointly develop a highly efficient, selective, oral fusion inhibitor for the treatment of RSV. In addition, Lianbio has also reached agreement on strategic collaboration with BridgeBio and Pfizer for joint commercialization of various innovative therapies in the Greater China region.

The sole investor from the Chinese Mainland, SDIC Investment Management Co., Ltd. joined hands with quite a few renowned biopharmaceutical funds in the world to jointly invest in Lianbio in 2020. In the past year, the company had also assisted Lianbio in analyzing the Chinese market to help Lianbio to better deploy its clinical product pipeline. At the same time, the company has also promoted coordination between its partner enterprises in the life science circle and Lianbio. The successful listing of Lianbio is expected to help Lianbio to continue to invest in its R&D, promote clinical progress and bridge the Chinese market with world's innovative medicines to benefit patients.